Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I rather if they update us on the progress on the dod clinical trails or atleast issue some sort of indication it’s under way
A few here are really sneaky
Yep 2025 will be huge year, as assuming this upcoming phase 2 SCI is successful, with all their publication efforts recently, they must be driving to exploit the ampakine platform into many more human trials. I know they have mentioned various orphan indications, but the big one is ADHD which is huge market and has shown past human trial success.
On top of that the gabakine KRM-ll-81 is superior to all in preclinicals, so how quickly they can secure grant funding and get that compound into humans will dictate how exponential the ride is for those of us who are invested here.
It should be noted that insiders and convertible holders have their shares at .0015 or higher. Warrants attached to loans to company need to see multiples of that to cover their loan basis. And those are bare minimum targets to see any reward for their risk. I would speculate we would see this well into the pennies before much is taken off the table by those who are invested in the science here and want to see this through various human clinical trials.
lol no wonder they are advertising that. Make sense advice jaded by the color envy
Eh, I doubt there are algorithms or traders that dumb to be short shares on a pharma stock with DOD funding a phase 2 trial next quarter. Which starts in about a week.
Of note the ampakine platform sold for 10 million + milestones a decade+ ago. RSPI got them all back and the technology to implement is stronger now and in combo with the government funding for phase 2 is readying for prime time, IMO. Maybe explains why there has been significant efforts to document and publicize all their efforts related to ampakines. Pouring fuel in the boosters.
Sell ur shares then boss. Holding mine till diamonds start erupting or the ground goes completely cold
Ur the only one that wants to get out this low be our guest lol
Yea but once you sold your shares you can’t buy them back. If this goes out of EM we trading multiples higher.
It's very hard to find a buyers willing to slap ask in expert market! It come and go...u need take advantage of it
Jus, I’m in RSPI for much higher prices.
.0004 x .002....u shoulda put sell .0019!! That buyer bid .0013 has no patience ..he slap ask!
Lol how tf is there naked shares on EM beyond wild😂
Now 10,000 lol at 0.002.
It’s showing 20,000 atm, but there is a 15min delay. Give me a second.
How much is on the ask now, should’ve blown past 002
Nice about one million bought at 0.002.
LT - I think you are right... 2025: hang on we are in for a helluva ride. RSPI has tapped into the most creative aspect of biotech - the graduate student. And by making available all of the ampakines for incredible prices. As I noted previously this preclinical research on the cheap is now poised for a number of molecules to go into more advance preclinical (e.g., monkeys) or clinical trials.
Interesting.
The Respire Pipeline only shows CX-1942 in addition to 717 and 1739 which are both shown as in phase 2. There clearly must be some impetus to essentially document and publicize all this past work and efforts related to the ampakine platform. It is not like they just did these studies in the past few years, much of the efforts look to be from quite awhile ago.
With the phase 2 SCI upcoming... logically there must be some preps for what is next assuming success. Phase 3, phase 2 ADHD? other orphan indications? Feels like they are prepping for a significant influx of interest in their ampakines!!!
It appears this paper is expanding that definition to include the two ampakines, one biologically active and the other inactive that together have a synergic effect to produce or accentuate a new or expanded biological effect. Synergistic: the interaction of two or more drugs when their combined effect is greater than the sum of the effects seen when each drug is given alone. I don't recall where I got the information that CX-1763 was no longer being investigated - obviously that source was wrong.
Any indication when this ticker will come back online via Market makers ? What's the hold up ?
In future text books, RSPI will be listed as an Anomoly.
Bid 1,900,000. 0.0013
Ask 110,000. 0.002
In human biology, do 2 or more distinct chemical entities often combine for efficaciousness?
"The water-soluble glycine ester pro-drug of CX1763, CX1942 is potent and active against alfentanil-induced respiratory depression in vivo"
My mind just exploded! How in hell did they come up with this? So, what this paper is saying is that the combination of CX1942/CX1763 produced a new drug that has extraordinary effects?.
pro-drug:
a biologically inactive compound which can be metabolized in the body to produce a drug.
I know that they have not PR'd really any of these publications coming out recently or made anyone aware of them, but it is now becoming clearer that they must be intending on doing something signifcant with the ampakine platform beyond this upcoming phase 2 SCI trial. Feels like they are really just summarizing all their past efforts. I could see them possibly look to sell the platform or spin it out into another entity similar to OSA.
Good Grief! Another one!
Curious: I have in my notes that CX-1763 was no longer being researched,
Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763
Future Medicinal Chemistry https://doi.org/10.1080/17568919.2024.2401312
Daniel P Radin, Sheng Zhong, Rok Cerne, Mohammed Shoaib, Jeffrey M Witkin, Arnold Lippa
Received 28 May 2024, Accepted 02 Sep 2024, Published online: 20 Sep 2024
Abstract
Aim: AMPA-glutamate receptor (AMPAR) dysfunction mediates multiple neurological/neuropsychiatric disorders. Ampakines bind AMPARs and allosterically enhance glutamate-elicited currents. This report describes the activity of the water-soluble ampakine CX1942 prodrug and the active moiety CX1763.
Results: CX1763 and CX1942 enhance synaptic transmission in hippocampi of rats. CX1763 increases attention in the 5CSRTT in rats and reduces amphetamine-induced hyperactivity in mice. CX1942 potently reverses opioid-induced respiratory depression in rats. CX1942/CX1763 was effective at 2.5–10 mg/kg. CX1763 lacked epileptogenicity up to 1500 mg/kg in rats.
Conclusion: These data document that CX1942 and CX1763 are active and without prominent side effects in multiple pre-clinical assays. CX1942 could serve as a prodrug for CX1763 with the advantage of high water solubility as in an intravenous formulation.
Article highlights
• The water-soluble glycine ester pro-drug of CX1763, CX1942 is potent and active against alfentanil-induced respiratory depression in vivo
• CX1942 and CX1763 produce a durable increase in hippocampal EPSP in vivo
• CX1763 increases metrics of attention in rodents while reducing hyperactivity associated with amphetamine, indicating multiple potential benefits for ADHD treatment
• CX1763/CX1942 is therapeutically active at doses of 2.5–10 mg/kg and CX1763 lacks epileptic and fatal toxicities up to 1500 mg/kg, demonstrating a notable safety margin, justifying further preclinical and clinical explorations
Well, of course. Cerne and Lippa are scientists and this focus on the science in their presentations. Get the science right (i.e., tolerance and efficacy in humans) and the rewards will follow. IMO RSPI with its multi-faceted pipeline will eventually be extraordinarily successful, even if there is a failure in one clinical trial. I consider myself extremely lucky to have been able to invest!
Lol highly doubt they even mention their association with EM. Bet they keep it focused on the drug and just brush past their advertisement of their stock. Probably somewhere in the speech will say in fine print lol ‘we are a publicly traded company.’ Technically it’s true since Canadian people can still buy in lol. Just touch on it vaguely lol. Got to love capitalism and cooperate America lol
A partnership would be great
RSPI working behind the scenes
I think it's worth mentioning that Dr. Lippa presented at the 5th annual installment of the same conference a couple years back, and that RespireRx representatives presented at the inaugural conference and the year two conference as well. So while exposure is a good thing it's probably not worth reading too much into their upcoming presentations in terms of gauging how far along their cannabinoid program is.
https://www.biospace.com/respirerx-pharmaceuticals-inc-announces-that-dr-arnold-lippa-is-an-invited-speaker-at-the-5th-international-cannabinoid-derived-pharmaceuticals-summit
https://markets.businessinsider.com/news/stocks/respirerx-pharmaceuticals-inc-executives-participating-in-the-2nd-annual-international-cannabinoid-derived-pharmaceuticals-summit-1028510435
https://www.marketscreener.com/quote/stock/RESPIRERX-PHARMACEUTICALS-5787161/news/RespireRx-Pharmaceuticals-Inc-Executives-Presenting-at-the-International-Cannabinoid-Derived-Pharma-27731174/
Says it was published the 20th, not sure if it's been posted before.
https://www.tandfonline.com/doi/full/10.1080/17568919.2024.2401312
Logically one would think they would update the public on the status of their OSA program and really the company in general before they bother presenting at this conference....
I mean if the most up to date information related to the company and the OSA program is appraoching a year old, would many attend?
Thanks for additional due diligence. Just more evidence that they are essentially summarizing their entire ampakine portfolio it appears. I am really wondering if they wont end up selling this platform at some point in time similar to what was done years ago with platform. Especially if this phase 2 SCI trial is successful, I think it opens a sh-ton of doors and avenues that a larger company could better navigate.
These look more like preclinical compounds and I would be curious where the company ranks them relative to CX1739 and CX717 which they list as phase 2 level candidates. Are these newer ones just backups, superior or tweaked for different medical indications than SCI/ADHD, etc?
Kind of an interesting presentation topic...
I wonder if the pro's and con's of the EM illiquid market will be discussed in relation to accessing talent and forming partnerships?
CB1, CB2 & Cannabinoid Drug Development Summit.
November 18-20, 2024 | Boston, MA
https://cannabinoid-derived-drug-development.com/speaker/jeff-margolis/
Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers
Daniel P. Radin, Rok Cerne, Jeffrey M. Witkin, Arnold Lippa
First published: 20 September 2024
https://doi.org/10.1002/cpdd.1475
Abstract
AMPA-type glutamate receptors (AMPARs) mediate the majority of fast excitatory synaptic transmission in the mammalian brain. Ampakines, positive allosteric modulators of AMPAR, hold significant potential for the treatment of a wide range of neurological/neuropsychiatric disorders in which excitatory synaptic transmission is compromised. Low-impact ampakines are a distinct subset of ampakines that accelerate channel opening yet minimally affect receptor desensitization, which may explain their lack of seizurogenic effects at therapeutic doses in preclinical models. CX1739 is a low-impact ampakine that has shown efficacy in preclinical studies. The current clinical study examined the tolerability and pharmacokinetics of CX1739 in healthy male volunteers in a 2-part study. Part A was a single dose escalation study (100-1200 mg, 48 patients) and Part B was a multiple dose ascending study (300-600 mg BID for 7-10 days, 32 patients). CX1739 was well tolerated up to 900 mg once daily (QD) and 450 mg twice a day, with the prominent side effects being headache and nausea. Importantly, the half-life of CX1739 was 6-9 hours, and Tmax was 1-5 hours. CX1739 Cmax and AUC were dose-proportional. These findings thus set the stage for further explorations of this drug candidate in phase 2 clinical studies.
Conflicts of Interest
RespireRx Pharmaceuticals is developing CX1739 for the treatment of opiate-induced respiratory depression, ADHD, and spinal cord injury. Daniel Radin, Rok Cerne, Jeffrey Witkin, and Arnold Lippa are associated with RespireRx, where Arnold Lippa is acting CEO, and Daniel P. Radin, Rok Cerne, and Jeffrey M. Witkin are non-paid researchers who occasionally conduct studies on these compounds.
Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763
Daniel P Radin, Sheng Zhong, Rok Cerne, Mohammed Shoaib, Jeffrey M Witkin & Arnold Lippa
Received 28 May 2024, Accepted 02 Sep 2024, Published online: 20 Sep 2024
Cite this article
https://doi.org/10.1080/17568919.2024.2401312
Abstract
Aim: AMPA-glutamate receptor (AMPAR) dysfunction mediates multiple neurological/neuropsychiatric disorders. Ampakines bind AMPARs and allosterically enhance glutamate-elicited currents. This report describes the activity of the water-soluble ampakine CX1942 prodrug and the active moiety CX1763.
Results: CX1763 and CX1942 enhance synaptic transmission in hippocampi of rats. CX1763 increases attention in the 5CSRTT in rats and reduces amphetamine-induced hyperactivity in mice. CX1942 potently reverses opioid-induced respiratory depression in rats. CX1942/CX1763 was effective at 2.5–10 mg/kg. CX1763 lacked epileptogenicity up to 1500 mg/kg in rats.
Conclusion: These data document that CX1942 and CX1763 are active and without prominent side effects in multiple pre-clinical assays. CX1942 could serve as a prodrug for CX1763 with the advantage of high water solubility as in an intravenous formulation.
Article highlights
The water-soluble glycine ester pro-drug of CX1763, CX1942 is potent and active against alfentanil-induced respiratory depression in vivo
CX1942 and CX1763 produce a durable increase in hippocampal EPSP in vivo
CX1763 increases metrics of attention in rodents while reducing hyperactivity associated with amphetamine, indicating multiple potential benefits for ADHD treatment
CX1763/CX1942 is therapeutically active at doses of 2.5–10 mg/kg and CX1763 lacks epileptic and fatal toxicities up to 1500 mg/kg, demonstrating a notable safety margin, justifying further preclinical and clinical explorations
I’ll take even just 0.54 per share
Folks, From the PhD thesis abstract that I posted yesterday:
1. GL-II-73, exhibits promising results in rodent models for depression treatment. It demonstrates excellent pharmacokinetic characteristics and displays antidepressant and anxiolytic effects in mice without inducing sedation or motor impairment typically associated with benzodiazepine drugs. Furthermore, it shows improved cognitive effects, which are crucial in treating depression or schizophrenia. Recent studies indicate that administering a single dose of GL-II-73 within 30 minutes can reverse stress-induced or age-related working memory deficits in old mice, restoring their performance levels to approximately 80-90%, nearly equivalent to those of young mice. Typically, old or stressed young mice perform at about 50-60%. Moreover, there was a remarkable reversal of brain cell shrinkage (dendrites and spines) in older mice, typically associated with aging, to a level similar to that of young mice. This exciting development occurred after two months of administering GL-II-73 in the drinking water of the older mice.
2. KRM-II-81 bioisosteres designed and synthesized, KPP-III-34 (8-bromo substituted imidazodiazepine) demonstrated improved target site (brain) exposure and metabolic stability in plasma and brain, leading to enhanced oral bioavailability ideal for pre-clinical studies. KPP-III-34 exhibited exceptional efficacy in various epilepsy models, including Lamotrigine-resistant seizure models, non-convulsive status epilepticus models, and chronic seizure models, via intraperitoneal (i.p.) or oral v administration in animals (mice or rats). Additionally, KPP-III-34 demonstrated a clean toxicity profile and selectively bound to the rat brain benzodiazepine receptor site without undesired binding to other receptors, according to PDSP (UNC) screens.
3. With these improved synthesis methods, we can now supply our collaborators with large quantities of these three a2/3-subtype selective GABAARs PAMs(KRM-II-81,KPP-III-34,DS-II-73 and MP-III-024 efficiently and with high quality.
RE 1 and 2: If show these same tolerance and efficacy in the clinic, will be, (dare I say it?) a societal change on the order of the industrial revolution and electronics revolution (including AI) will be upon us.. WE are on the verge of countering many cogitative disabilities include brain aging (memory loss). RE 3: manufacturing these molecules apparently will not prevent this revolution ! IMO, of course!!!
A long way from that dream, but...
These assets have that potential. This company needs to get current and secure some level or round of financing to support BOTH ampakine and gabakine programs as they are both moving into human clinicals where exponential leaps in valuation occur. They need to grow the awareness and investor base to be in position to leverage their valuable assets to obtain the resources and partnerships to continue exploiting the assets through various clinical trials and new medical indications. The better the foundation the more equity in the assets they retain until a point in time BP takes over.
Serious endeavours and assets require serious people where appearance matters. Looking forward to watching this company blossom in the coming months and well into 2025 as these assets enter various human clinical trials.
Followers
|
349
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
51695
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |